stockrow
Friday 6 November 2026
Export IDYA’s income statement to Excel — free account
IDEAYA Biosciences, Inc.
IDYA Healthcare Biotechnology
IDEAYA Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $218.7 million, up 3,024.4% from fiscal 2024.
- Revenue
- −95.1%
- EPS
- −190.5%
- Free cash flow
- −165.9%
Quarter to September 2026, against a year earlier
31.20
0.55
+1.79%
Follow IDYA
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
| (38.46%) | (16.22%) | (14.28%) | (10.92%) |
+8 more TTM periods Free account |
|
| (34.98%) | (14.89%) | (13.14%) | (10.18%) | ||
ROIC |
(114.15%) | (36.65%) | (43.10%) | (25.96%) | |
Return on Tangible Assets |
(53.61%) | (22.16%) | (21.89%) | (18.45%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(3.40) | (1.24) | (0.99) | (0.83) | |
Free Cash Flow |
(349.80) | (113.87) | (87.93) | (73.47) | |
Capital Expenditures |
(2.44) | (2.21) | (2.00) | (2.37) | |
| Other line items | |||||
Cash ROIC |
(18.12%) | (5.62%) | (5.47%) | (4.42%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1,129.30% | 159.75% | 148.15% | 136.43% | |
Selling, General and Administrative Expense of Revenue |
238.08% | 32.92% | 30.19% | 27.45% | |
Share Based Compensation of Revenue |
166.19% | 23.58% | 22.00% | 19.99% | |
Operating CF/Net income |
0.83 | 0.64 | 0.61 | 0.63 | |
Depreciation/Fixed assets |
(0.06) | (0.15) | (0.32) | (0.66) | |
Capex/Depreciation |
5.17 | 1.77 | 0.71 | 0.44 | |
Revenue per Share |
0.35 | 2.54 | 2.58 | 2.61 | |
Operating CF per Share |
(3.37) | (1.21) | (0.97) | (0.80) | |
Capex per Share |
(0.02) | (0.02) | (0.02) | (0.03) | |
Capex to Sales |
0.07 | 0.01 | 0.01 | 0.01 |
Columns are period end dates · fundamentals updated 5 Nov 2026